Fragile X syndrome patients with prematuration had a much earlier onset of neurological problems, including earlier symptoms of neurodegeneration. They also experienced emotional processing problems. Some of the most common emotional processing disorders reported were mood regulation, anxiety, and psychosis.
According to researchers, a drug approved by the FDA may reverse some of the symptoms associated with Fragile X syndrome. The drug can reverse hyper-excitability that leads to sensory hypersensitivity.
A new neuroimaging study reveals babies with Fragile X syndrome have less developed white matter in the brain compared to children without the condition.
Researchers report neurons in mice with a genetic defect that causes Fragile X are similar to those in mice without the syndrome, but fail to interact correctly. This failure results in the cognitive impairment associated with FXS.
A new study reports children with Fragile X syndrome show bias toward threatening rather than positive emotion.